These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 30300440)

  • 61. An outbreak of infection due to beta-Lactamase Klebsiella pneumoniae Carbapenemase 2-producing K. pneumoniae in a Greek University Hospital: molecular characterization, epidemiology, and outcomes.
    Souli M; Galani I; Antoniadou A; Papadomichelakis E; Poulakou G; Panagea T; Vourli S; Zerva L; Armaganidis A; Kanellakopoulou K; Giamarellou H
    Clin Infect Dis; 2010 Feb; 50(3):364-73. PubMed ID: 20041768
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment.
    Zarkotou O; Pournaras S; Tselioti P; Dragoumanos V; Pitiriga V; Ranellou K; Prekates A; Themeli-Digalaki K; Tsakris A
    Clin Microbiol Infect; 2011 Dec; 17(12):1798-803. PubMed ID: 21595793
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Clinical Evaluation of Meropenem-Vaborbactam Combination for the Treatment of Urinary Tract Infection: Evidence to Date.
    Herald F; Burgos RM
    Infect Drug Resist; 2023; 16():555-568. PubMed ID: 36726388
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Combination therapy with polymyxin B for carbapenemase-producing Klebsiella pneumoniae bloodstream infection.
    Medeiros GS; Rigatto MH; Falci DR; Zavascki AP
    Int J Antimicrob Agents; 2019 Feb; 53(2):152-157. PubMed ID: 30722960
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Efficacy and Safety of Meropenem-Vaborbactam Versus Best Available Therapy for the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Patients Without Prior Antimicrobial Failure: A Post Hoc Analysis.
    Bassetti M; Giacobbe DR; Patel N; Tillotson G; Massey J
    Adv Ther; 2019 Jul; 36(7):1771-1777. PubMed ID: 31098989
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy.
    Tumbarello M; Viale P; Viscoli C; Trecarichi EM; Tumietto F; Marchese A; Spanu T; Ambretti S; Ginocchio F; Cristini F; Losito AR; Tedeschi S; Cauda R; Bassetti M
    Clin Infect Dis; 2012 Oct; 55(7):943-50. PubMed ID: 22752516
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Bloodstream infections caused by Klebsiella pneumoniae: prevalence of bla
    Xu M; Fu Y; Kong H; Chen X; Chen Y; Li L; Yang Q
    BMC Infect Dis; 2018 Jul; 18(1):358. PubMed ID: 30064360
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial.
    Harris PNA; Tambyah PA; Lye DC; Mo Y; Lee TH; Yilmaz M; Alenazi TH; Arabi Y; Falcone M; Bassetti M; Righi E; Rogers BA; Kanj S; Bhally H; Iredell J; Mendelson M; Boyles TH; Looke D; Miyakis S; Walls G; Al Khamis M; Zikri A; Crowe A; Ingram P; Daneman N; Griffin P; Athan E; Lorenc P; Baker P; Roberts L; Beatson SA; Peleg AY; Harris-Brown T; Paterson DL;
    JAMA; 2018 Sep; 320(10):984-994. PubMed ID: 30208454
    [TBL] [Abstract][Full Text] [Related]  

  • 69. In vitro evaluation of meropenem-vaborbactam against clinical CRE isolates at a tertiary care center with low KPC-mediated carbapenem resistance.
    Kinn PM; Chen DJ; Gihring TM; Schulz LT; Fox BC; McCreary EK; Lepak AJ
    Diagn Microbiol Infect Dis; 2019 Mar; 93(3):258-260. PubMed ID: 30344065
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Polymyxin B in combination with meropenem against carbapenemase-producing Klebsiella pneumoniae: pharmacodynamics and morphological changes.
    Sharma R; Patel S; Abboud C; Diep J; Ly NS; Pogue JM; Kaye KS; Li J; Rao GG
    Int J Antimicrob Agents; 2017 Feb; 49(2):224-232. PubMed ID: 28040408
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Risk factors for infection and predictors of mortality among patients with KPC-producing Klebsiella pneumoniae bloodstream infections in the intensive care unit.
    Papadimitriou-Olivgeris M; Marangos M; Christofidou M; Fligou F; Bartzavali C; Panteli ES; Vamvakopoulou S; Filos KS; Anastassiou ED
    Scand J Infect Dis; 2014 Sep; 46(9):642-8. PubMed ID: 25017796
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Pharmacokinetics of continuous-infusion meropenem for the treatment of Serratia marcescens ventriculitis in a pediatric patient.
    Cies JJ; Moore WS; Calaman S; Brown M; Narayan P; Parker J; Chopra A
    Pharmacotherapy; 2015 Apr; 35(4):e32-6. PubMed ID: 25884534
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of the β-Lactamase Inhibitor Vaborbactam (RPX7009) in Healthy Adult Subjects.
    Griffith DC; Loutit JS; Morgan EE; Durso S; Dudley MN
    Antimicrob Agents Chemother; 2016 Oct; 60(10):6326-32. PubMed ID: 27527080
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Pharmacokinetics of continuous-infusion meropenem in a pediatric patient receiving extracorporeal life support.
    Cies JJ; Moore WS; Dickerman MJ; Small C; Carella D; Chopra A; Parker J
    Pharmacotherapy; 2014 Oct; 34(10):e175-9. PubMed ID: 25146254
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A descriptive pharmacokinetic/pharmacodynamic analysis of continuous infusion meropenem/vaborbactam in the treatment of critically ill patients with documented KPC-producing Klebsiella pneumoniae ventilator-associated pneumonia.
    Gatti M; Rinaldi M; Gaibani P; Siniscalchi A; Tonetti T; Viale P; Pea F
    Int J Antimicrob Agents; 2023 Nov; 62(5):106992. PubMed ID: 37778429
    [No Abstract]   [Full Text] [Related]  

  • 76. [Impact of extended-spectrum β-lactamase on clinical outcome and medical cost in patients with bloodstream infection due to Klebsiella pneumoniae].
    Li JQ; Tang CQ; Wang H; Ji SZ; Lü KY; Xiao SC; Deng AM; Huang Y; Xia ZF
    Zhonghua Yi Xue Za Zhi; 2016 Jun; 96(24):1903-6. PubMed ID: 27373357
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant
    Petty LA; Henig O; Patel TS; Pogue JM; Kaye KS
    Infect Drug Resist; 2018; 11():1461-1472. PubMed ID: 30254477
    [TBL] [Abstract][Full Text] [Related]  

  • 78. New Polymyxin B Dosing Strategies To Fortify Old Allies in the War against KPC-2-Producing Klebsiella pneumoniae.
    Bulman ZP; Satlin MJ; Chen L; Kreiswirth BN; Shin BS; Walsh TJ; Holden PN; Forrest A; Nation RL; Li J; Tsuji BT
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167549
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Outcomes of transplantation using organs from a donor infected with Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae.
    Ariza-Heredia EJ; Patel R; Blumberg EA; Walker RC; Lewis R; Evans J; Sankar A; Willliams MD; Rogers J; Milano C; Razonable RR
    Transpl Infect Dis; 2012 Jun; 14(3):229-36. PubMed ID: 22624726
    [TBL] [Abstract][Full Text] [Related]  

  • 80. An evaluation of meropenem/vaborbactam for the treatment of nosocomial pneumonia.
    Groft LM; Claeys KC; Heil EL
    Expert Opin Pharmacother; 2021 Feb; 22(3):265-271. PubMed ID: 33090037
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.